More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

How are small molecules & biologics trending among new drug approvals and potential blockbuster drugs? Will biologics overtake small molecules as the leading modality, and if so, in what areas? DCAT Value Chain Insights takes the pulse of the...

Despite significant disruption and reprioritization of clinical trial activity during 2020 due to COVID-19, R&D activity levels remained at historically high levels, driven by new funding and strategic transactions, especially within oncology,...

The European Commission has updated the EU’s Industrial Strategy, which was first put forth in March 2020 with goals of realizing a green and digital economy while increasing the EU’s global competitiveness. The strategy involves improving...

The bio/pharma industry is based on batch manufacturing, so how is the adoption of continuous manufacturing for drug substances and drug products progressing? A pending ICH guideline clarifies technical and regulatory issues. And, views from the...

What has been the impact of COVID-19 on bio/pharmaceutical companies’ bottom line? For companies successfully bringing products for COVID-19 to fruition, 1Q 2021 results have been positive. What is expected for the rest of 2021? DCAT Value Chain...

Three-dimensional (3D) printing is an emerging technology across multiple industries, including the bio/pharmaceutical industry. To date, one drug using 3D printing has been approved by the FDA. What’s behind the technology, and what is the...

While liquid-filled hard capsules (LFHCs) have been around for decades, today’s difficult APIs and increased competition have rekindled interest in this versatile and value-added dosage form. LFHCs’ long list of advantages can have a significant...

The European Parliament formally approved last month the EU–UK pact under Brexit, which governs trade and customs issues. The pact has been applied conditionally since the beginning of 2021, but there are some concerns about its implementation....